Raymond James Financial Services Advisors, Inc. - NOVOCURE LTD ownership

NOVOCURE LTD's ticker is NVCR and the CUSIP is G6674U108. A total of 230 filers reported holding NOVOCURE LTD in Q3 2023. The put-call ratio across all filers is 0.71 and the average weighting 0.1%.

Quarter-by-quarter ownership
Raymond James Financial Services Advisors, Inc. ownership history of NOVOCURE LTD
ValueSharesWeighting
Q2 2023$364,744
-50.4%
8,789
-28.1%
0.00%0.0%
Q1 2023$735,572
-12.5%
12,231
+6.7%
0.00%
-50.0%
Q4 2022$840,664
+2.9%
11,461
+6.6%
0.00%0.0%
Q3 2022$817,000
+7.9%
10,749
-1.3%
0.00%0.0%
Q2 2022$757,000
-18.3%
10,888
-2.7%
0.00%0.0%
Q1 2022$927,000
+5.1%
11,186
-4.7%
0.00%0.0%
Q4 2021$882,000
-62.7%
11,741
-42.4%
0.00%
-60.0%
Q3 2021$2,367,000
-56.4%
20,373
-16.7%
0.01%
-54.5%
Q2 2021$5,424,000
+69.9%
24,451
+1.2%
0.01%
+57.1%
Q1 2021$3,193,000
-27.5%
24,159
-5.1%
0.01%
-36.4%
Q4 2020$4,406,000
+54.9%
25,461
-0.4%
0.01%
+37.5%
Q3 2020$2,844,000
+91.3%
25,551
+1.9%
0.01%
+60.0%
Q2 2020$1,487,000
-32.3%
25,082
-23.1%
0.01%
-50.0%
Q1 2020$2,196,000
-23.4%
32,605
-4.2%
0.01%
+11.1%
Q4 2019$2,868,000
+24.7%
34,034
+10.7%
0.01%
+12.5%
Q3 2019$2,299,000
+87.5%
30,744
+58.6%
0.01%
+60.0%
Q2 2019$1,226,000
+32.1%
19,385
+0.7%
0.01%
+25.0%
Q1 2019$928,000
+32.0%
19,258
-8.3%
0.00%0.0%
Q4 2018$703,000
-34.5%
20,991
+2.5%
0.00%
-20.0%
Q3 2018$1,073,000
+266.2%
20,478
+118.8%
0.01%
+400.0%
Q2 2018$293,0009,3580.00%
Other shareholders
NOVOCURE LTD shareholders Q3 2023
NameSharesValueWeighting ↓
Invus Financial Advisors, LLC 350,884$29,071,00012.94%
HARTLINE INVESTMENT CORP/ 302,194$67,033,0008.47%
Deep Track Capital, LP 1,000,000$82,850,0005.31%
MORGAN JESS S & CO INC 48,860$4,048,0002.94%
Taylor Frigon Capital Management LLC 73,014$6,049,0002.24%
Private Harbour Investment Management & Counsel, LLC 13,263$1,099,0000.92%
HighVista Strategies LLC 17,448$1,446,0000.92%
COURAGE CAPITAL MANAGEMENT LLC 10,000$829,0000.79%
Lloyd Park, LLC 6,700$555,0000.61%
Rhenman & Partners Asset Management AB 69,700$5,775,0000.57%
View complete list of NOVOCURE LTD shareholders